Vitamin B6

For general supplementation, stay at or below the tolerable upper limit of 100 mg/day synthetic pyridoxine. The RDA is 1.3–1.7 mg/day for adults, easily met by diet or any B-complex. Specific indications may justify higher doses: nausea of pregnancy (10–40 mg/day with doxylamine, as Diclegis), INH prophylaxis (25–50 mg/day), premenstrual syndrome (50–100 mg/day), homocysteine lowering (25–50 mg/day with folate and B12), and specialist-directed very high doses (100–500 mg/day) for homocystinuria, sideroblastic anemia, and pyridoxine-dependent epilepsy. Chronic doses above 200 mg/day have been associated with sensory peripheral neuropathy that may not fully reverse on stopping, described by Schaumburg 1983 and confirmed in subsequent cases (PMID 6344712). Any sensory symptoms (tingling, burning, unsteadiness) on chronic high-dose B6 should prompt immediate dose reduction.

Yes — B6 is first-line for nausea and vomiting of pregnancy. Pyridoxine 25 mg three times daily was established as effective by Sahakian 1991 (PMID 1895728), and the combination of pyridoxine 10 mg + doxylamine 10 mg (Diclegis, Bonjesta) is ACOG first-line for NVP with excellent safety and efficacy data over decades of use (PMID 24752170). Dose escalation up to 4 Diclegis tablets daily (40 mg pyridoxine + 40 mg doxylamine total) is standard if initial dosing is inadequate. If doxylamine is unavailable or causes excessive sedation, pyridoxine alone at 25 mg three times daily is effective. These doses have no association with birth defects across decades of use and millions of patient-years of exposure — Diclegis was approved by FDA in 2013 as the first Pregnancy Category A drug for NVP after extensive safety review.

Pyridoxine HCl is the standard supplemental form, inexpensive and the basis of the outcome evidence for NVP, INH prophylaxis, and most clinical uses. P5P (pyridoxal 5-phosphate) is the active coenzyme form and is marketed as 'pre-activated' B6 — biochemically true but somewhat misleading in practice, because P5P must be dephosphorylated at the gut lumen before absorption as pyridoxal, then re-phosphorylated intracellularly to PLP. For most healthy people, pyridoxine HCl and P5P both achieve adequate tissue PLP levels and there's no dramatic practical difference. P5P may have specific advantage in PNPO (pyridoxine 5-phosphate oxidase) deficiency, a rare pediatric syndrome where pyridoxine can't convert to PLP and PLP or pyridoxal must be supplied directly. For general supplementation, pyridoxine HCl is fine and cheaper.

At chronic high doses, yes. Schaumburg 1983 described a sensory peripheral neuropathy / ganglionopathy syndrome in patients taking multi-gram pyridoxine doses over months to years, with burning dysesthesias, gait unsteadiness, and reduced proprioception (PMID 6344712). Subsequent cases have documented the syndrome at chronic doses as low as 200 mg/day over months. This is why the tolerable upper limit is set at 100 mg/day — below this, neuropathy risk is minimal. Therapeutic use at NVP doses (up to 40 mg/day), INH prophylaxis (25–50 mg/day), or short-term higher doses are generally safe, but chronic supplementation above 100 mg/day without specific clinical indication should be avoided, and sensory symptoms (tingling, burning, unsteadiness) on any dose should prompt dose reduction or cessation. Recovery after stopping may be partial.

Yes at RDA range, and generally yes at pharmacologic doses if you're on modern combination therapy. The classical 'avoid B6 in Parkinson's' guidance came from pure levodopa therapy — B6 accelerates peripheral decarboxylation of levodopa via aromatic amino acid decarboxylase (AADC), reducing the fraction reaching the CNS. Modern Parkinson regimens use carbidopa-levodopa (Sinemet) or benserazide-levodopa, which peripherally inhibit AADC and largely eliminate this interaction. Patients on modern combination levodopa can safely take standard B-complex or multivitamin doses of B6. Pure levodopa therapy is essentially obsolete in modern practice; if you're somehow on pure levodopa, avoid pharmacologic B6.

Mixed evidence. Ellis and colleagues in the 1980s popularized pyridoxine 200–300 mg/day for CTS based on a neuropathy-reversal hypothesis, but controlled trials have been equivocal, and mainstream neurology does not consider B6 standard CTS therapy. Wrist splinting, steroid injection, and surgical decompression have much stronger evidence. Some patients with borderline B6 status may benefit from repletion, and a trial of B6 200 mg/day for 2–3 months is low-risk if you're willing to monitor for sensory symptoms (which would paradoxically mimic or worsen CTS). For most CTS, go directly to standard therapies — splinting first, then injection or surgery as needed — rather than relying on B6.

Modestly. Wyatt 1999 meta-analysis and subsequent work support modest benefit of B6 up to 100 mg/day for premenstrual syndrome symptoms including mood, breast tenderness, and bloating (PMID 10334745). Effect sizes are small and not as strong as for SSRIs, GnRH analogs, or hormonal therapies. If you have mild-to-moderate PMS and want to try B6, 50–100 mg/day during the luteal phase only (days 14–28 of cycle) is reasonable with attention to any sensory symptoms that would warrant stopping. Going above 100 mg/day for PMS lacks clear incremental benefit and carries neuropathy risk at chronic multi-month use.

Yes, if homocysteine lowering is the goal. The classic stack is folate 400–800 mcg + B12 500–1,000 mcg + B6 25–50 mg daily, which reliably lowers homocysteine by 20–30%. B6 supports the transsulfuration pathway via cystathionine beta-synthase (CBS), complementing folate and B12 which support the remethylation pathway. However, as extensively discussed in the Folate entry, the major cardiovascular outcome trials (NORVIT, HOPE-2, VISP, SEARCH, WAFACS) did not show reduced CV events with homocysteine lowering in folate-replete populations (PMID 16531614, 17024074). The stack remains relevant for hyperhomocysteinemia documentation, homocystinuria, and possibly stroke prevention in folate-deficient populations (CSPPT Chinese trial, PMID 25713862), but is not recommended for generalized CV prevention.

Poultry (chicken breast ~0.5 mg per 3 oz), fish (tuna, salmon ~0.9 mg per 3 oz), beef liver (~0.9 mg per 3 oz), potatoes (~0.4 mg per medium baked potato), bananas (~0.4 mg each), chickpeas (~1.1 mg per cup cooked), pistachios (~1.1 mg per cup), fortified breakfast cereals (typically 0.5–2 mg per serving), sweet potatoes, avocado, and leafy greens. Most omnivores eating any combination of poultry, fish, and starchy vegetables meet the 1.3–1.7 mg RDA from food alone. Vegans and vegetarians generally do fine on B6 from legumes, grains, and fortified foods. Deficiency in healthy omnivores is uncommon; risk contexts include chronic alcoholism, isoniazid use, theophylline use, chronic kidney disease on dialysis, and inflammatory bowel disease with malabsorption.

Not established as monotherapy. B6 deficiency can contribute to depressed mood via impaired synthesis of serotonin, dopamine, and GABA (all PLP-dependent), and correcting confirmed B6 deficiency can improve mood. For non-deficient patients with clinical depression, B6 supplementation has not been shown to reliably treat depression in rigorous trials. The evidence for B vitamins in depression is stronger for Folate (especially L-methylfolate as SSRI augmentation at 7.5–15 mg/day per Papakostas 2012, PMID 23137033) and for the general methylation/homocysteine stack. If you have depression and are concerned about B vitamin status, a standard B-complex providing RDA-range B6, B12, and folate is reasonable; high-dose B6 alone is not an evidence-supported depression treatment.